Business Wire

Colicity Inc. Announces Closing of $345 Million Initial Public Offering

27.2.2021 01:00:00 EET | Business Wire | Press release

Share

Colicity Inc. (the “Company”) announced the closing today of its initial public offering of 34,500,000 units, including the underwriters’ exercise of their full over-allotment option for 4,500,000 units, at a price of $10.00 per unit. The units are listed on the NASDAQ Stock Market (NASDAQ) and began trading under the ticker symbol “COLIU” on February 24, 2021. Each unit consists of one Class A share and one-fifth of one redeemable warrant, with each whole warrant exercisable to purchase one Class A share at a price of $11.50 per share. Only whole warrants will be exercisable. Once the securities comprising the units begin separate trading, the Class A shares and warrants are expected to be listed on the NASDAQ under the symbols “COLI” and “COLIW,” respectively.

Colicity Inc. is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus on businesses that operate within the Technology, Media and Telecommunications sectors and is led by veteran communications and technology entrepreneur, Craig O. McCaw, who is Colicity’s Chairman and CEO, and Randy Russell, Colicity’s Chief Investment Officer.

Goldman Sachs & Co. LLC and PJT Partners LP were the joint book-running managers of the offering. The Company has granted the underwriters a 45-day option to purchase up to an additional 4,500,000 units at the initial public offering price to cover over-allotments if any.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on February 23, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering was made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, email: prospectus-ny@ny-email.gs.com, or telephone: 1-866-471-2526.

Cautionary Note Concerning Forward-Looking Statements This press release contains statements that constitute “forward-looking statements,” including with respect to the initial public offering and search for an initial business combination. No assurance can be given that the proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement for the initial public offering filed with the SEC. Copies are available on the SEC’s website, https://www.sec.gov/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Please direct all inquiries regarding Colicity Inc. to Todd Wolfenbarger at twolfenbarger@summitslc.com / (801) 244-9600.

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements15.6.2026 13:00:00 EEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the "Notification Letter"), from Hearing Advisor of The Nasdaq Stock Market LLC., indicating that the Company has regained compliance with Listing Rule 5250(c)(1) and that the Company is therefore in compliance with the Nasdaq Global Market's listing requirements. As noted in the Hearing Panel's May 20, 2026 compliance determination, the Company remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027. The Company filed its annual report on Form 20-F for the year ended December 31, 2025 on June 5, 2026. The Notification Letter also stated that the hearing before the Hearings Panel, applied for by the Company, had accordingly been canceled. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission

KRM22 partners with Sigma AI to enhance market surveillance and risk intelligence capabilities15.6.2026 13:00:00 EEST | Press release

KRM22, the technology and software investment company focused on risk management solutions for capital markets, today announced a strategic partnership with Sigma AI, a leading provider of AI-driven financial insights, to integrate advanced news sentiment analytics into its risk management application suite. The integration marks a significant enhancement to KRM22’s capabilities, enabling clients to incorporate real-time market sentiment insights derived from global news sources directly into their risk frameworks. By leveraging Sigma AI’s proprietary natural language processing and machine learning models, KRM22 will help firms better identify emerging risks, anticipate market-moving events, and make more informed trading and compliance decisions. Advancing risk management through AI-driven sentiment analysis As part of the first phase of the collaboration, KRM22 will embed Sigma AI’s news sentiment engine within its application suite. This will provide users with actionable intellige

HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 12:15:00 EEST | Press release

HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612936893/en/ HUI (HUI:VSE) merges traditional and crypto finance: commences continuous trading in Vienna with leading market maker and announces impending token listing on major global exchange Emmanuelle Deba

Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 10:35:00 EEST | Press release

India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of its farming population. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202606151544

Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 10:00:00 EEST | Press release

Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discovery teams to accelerate decision-making, streamline workflows, and advance programs more efficiently from hit identification through lead optimization. "Drug discovery increasingly requires seamless integration between chemistry and biology," said Michael Dabrowski, Chief Executive Officer of Pelago Bioscience. "By bringing RG Discovery

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye